

Acute Graft-versus-Host Disease - Pipeline Insight, 2021

<https://marketpublishers.com/r/A5C6C1DEA119EN.html>

Date: October 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: A5C6C1DEA119EN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Acute Graft-versus-Host Disease - Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Acute Graft-versus-Host Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Acute Graft-versus-Host Disease Understanding

Acute Graft-versus-Host Disease: Overview

Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplant (AHscT) is an immune triggered process, leading to profound immune dysregulation and organ dysfunction. The symptoms of Acute Graft-versus-host disease include maculopapular rash, hyperbilirubinemia with jaundice due to damage to the small bile ducts, leading to cholestasis; nausea, vomiting, and anorexia, watery or bloody diarrhea, and crampy abdominal pain. The diagnosis of acute GVHD relies on the assessment of target organs by means of clinical and laboratory analyses and biopsy. Acute GVHD is typically treated with a class of medication called glucocorticoids

(steroids) and cyclosporine (immunosuppressive drugs).

'Acute Graft-versus-Host Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Graft-versus-Host Disease pipeline landscape is provided which includes the disease overview and Acute Graft-versus-Host Disease treatment guidelines. The assessment part of the report embraces, in depth Acute Graft-versus-Host Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Graft-versus-Host Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Graft-versus-Host Disease R&D. The therapies under development are focused on novel approaches to treat/improve Acute Graft-versus-Host Disease.

Acute Graft-versus-Host Disease Emerging Drugs Chapters

This segment of the Acute Graft-versus-Host Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Graft-versus-Host Disease Emerging Drugs

RGI-2001: Regimmune

RGI-2001 is a liposomal formulation of KRN7000, an alpha-galactosylceramide analog, embedded within the lipid bilayer to promote uptake by antigen presenting cells and presentation by CD1d. The drug is in Phase II clinical studies for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following Allogeneic Hematopoietic Stem Cell

Transplantation (alloHSCT).

MaaT013: MaaT Pharma

MaaT013 is a donor-derived, standardized, high-richness, high-diversity microbiome ecosystem therapy, containing Butycore, a group of bacterial species known to produce anti-inflammatory short-chain-fatty acids. The drug is in Phase III clinical studies for the treatment of ruxolitinib refractory GI-aGVHD.

Further product details are provided in the report.....

Acute Graft-versus-Host Disease: Therapeutic Assessment

This segment of the report provides insights about the different Acute Graft-versus-Host Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Graft-versus-Host Disease

There are approx. 20+ key companies which are developing the therapies for Acute Graft-versus-Host Disease. The companies which have their Acute Graft-versus-Host Disease drug candidates in the most advanced stage, i.e. Phase III include, MaaT Pharma.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Acute Graft-versus-Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

Acute Graft-versus-Host Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Acute Graft-versus-Host Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Graft-versus-Host Disease drugs.

Acute Graft-versus-Host Disease Report Insights

Acute Graft-versus-Host Disease Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Acute Graft-versus-Host Disease Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Acute Graft-versus-Host Disease drugs?

How many Acute Graft-versus-Host Disease drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Graft-versus-Host Disease?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Graft-versus-Host Disease therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Acute Graft-versus-Host Disease and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Oncolmmune (Merck)

MaaT Pharma

CSL Behring

Equillium

Roche

Cellect Biotechnology

Bristol-Myers Squibb

Takeda

Regimmune

AltruBio

Incyte Corporation

Chia Tai Tianqing Pharmaceutical

Kalytera Therapeutics

ASC Therapeutics

medac GmbH

Key Products

MC0518

ASC-930

MK 7110

MaaT013

Alpha-1-antitrypsin

Itolizumab

UTTR1147A

Allogeneic MPBC transplantation from matched related donor

Letolizumab

Vedolizumab

RGI-2001

Neihulizumab

Itacitinib + Tocilizumab

TQ05105

CBD

Contents

Introduction

Executive Summary

Acute Graft-versus-Host Disease: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Acute Graft-versus-Host Disease – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

MaaT013: MaaT Pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

RGI-2001: Regimmune

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I/II)

Comparative Analysis

Itolizumab: Equillum

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Acute Graft-versus-Host Disease Key Companies
Acute Graft-versus-Host Disease Key Products
Acute Graft-versus-Host Disease- Unmet Needs
Acute Graft-versus-Host Disease- Market Drivers and Barriers
Acute Graft-versus-Host Disease- Future Perspectives and Conclusion
Acute Graft-versus-Host Disease Analyst Views
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Acute Graft-versus-Host Disease

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Acute Graft-versus-Host Disease

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Acute Graft-versus-Host Disease - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/A5C6C1DEA119EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A5C6C1DEA119EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970